Cutanos GmbH has developed an innovative technology known as the Langerhans Cell Targeted Delivery System (LC-TDS), which is designed to enhance precision medicine through targeted mRNA delivery to immune cells, specifically dendritic cells. This novel platform utilizes a ligand-based approach to direct lipid nanoparticle (LNP) formulations to Langerhans cells, a specific type of dendritic cell that plays a crucial role in immune modulation. The LC-TDS is distinguished by its modular design, allowing for flexible adaptation to various applications, which enhances its compatibility with other technologies. A significant advantage of this system is its minimally invasive administration method, utilizing microneedles or microinjectors for injury-free delivery through the skin, thereby improving patient compliance and safety.

In addition to its core technology, Cutanos is actively engaged in various in-house and collaborative projects that leverage the modular nature of the LC-TDS platform. These projects aim to explore a range of immunity-driven indications, contributing to a deeper understanding of the underlying biological mechanisms. The company is focused on advancing its technology to improve the efficacy and stability of next-generation vaccines, particularly in the context of infectious diseases. By prioritizing innovative solutions that enhance vaccine acceptance and accessibility, Cutanos is positioned to make a significant impact in the field of immunology and vaccine development.

Austria

We are a young biotech start-up located in Vienna, Austria focusing on targeted drug delivery systems to develop new immunotherapies – such as anti-viral vaccines and treatments for autoimmune diseases.

Cutanos GmbH

Company Details